Drug:
Reaction: INJECTION SITE PAIN
20250101 - 20251231
No. 401 - 500
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 401 | 25119168 |
US |
8 | 2 |
Injection site pain, |
||||
DUPILUMAB, |
||||
| 402 | 25119181 |
US |
70 | 1 |
Injection site pain, Incorrect dose administered, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 403 | 25119225 |
US |
53 | 2 |
Injection site pain, Injection site bruising, |
||||
DUPILUMAB, |
||||
| 404 | 25119249 |
US |
69 | 2 |
Pruritus, Injection site pain, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, |
||||
| 405 | 25119265 |
US |
2 | |
Injection site pain, Product knowledge deficit, Device use error, Device breakage, |
||||
SOMATROPIN, SOMATROPIN, |
||||
| 406 | 25119357 |
US |
1 | |
Gynaecomastia, Breast mass, Skin burning sensation, Pruritus, Injection site pain, Inappropriate schedule of product administration, |
||||
DUPILUMAB, ALFUZOSIN HYDROCHLORIDE, CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE OINTMENT USP, 0.05%, APIXABAN, FINASTERIDE, HYDROCORTISONE, ANTIPRURITIC (ANTI-ITCH), ANTI-ITCH CREAM, HYDROCORTISONE 1%, HYDROCORTISONE CONTINUOUS SPRAY, ANTI-PRURITIC, HYDROCORTISONE LOTION, HYDROCORTISONE ACETATE, HYDROCORTISONE LOTION KIT, ANTI ITCH, ANTI-ITCH, COOL RELIEF GEL WITH ALOE, HYDROCORTISONE CREAM 1%, HYDROCORTISONE SPRAY, DRS. HYDROCORTISONE, EMPAGLIFLOZIN, LEVOTHYROXINE, LOSARTAN POTASSIUM, LOSARTAN, MUPIROCIN, MUPIROCIN CALCIUM, SPIRONOLACTONE, TORSEMIDE, |
||||
| 407 | 25119799 |
FR |
39 | 1 |
Angioedema, Injection site oedema, Injection site pain, Injection site pruritus, |
||||
IXEKIZUMAB, |
||||
| 408 | 25119836 |
US |
50 | 1 |
Injection site pain, |
||||
DUPILUMAB, |
||||
| 409 | 25119931 |
US |
2 | |
Injection site mass, Injection site pain, Product use in unapproved indication, |
||||
DUPILUMAB, |
||||
| 410 | 25119985 |
US |
2 | |
Injection site pain, |
||||
SUMATRIPTAN SUCCINATE, |
||||
| 411 | 25119994 |
US |
58 | 2 |
Gastrointestinal stoma output increased, Injection site bruising, Injection site pain, Malaise, Incorrect dose administered, Product dose omission in error, |
||||
TEDUGLUTIDE, TEDUGLUTIDE, TEDUGLUTIDE, TEDUGLUTIDE, |
||||
| 412 | 25120207 |
US |
63 | 2 |
Injection site pain, Injection site reaction, |
||||
TIRZEPATIDE, |
||||
| 413 | 25120213 |
US |
78 | 1 |
Throat clearing, Cough, Eye pruritus, Incorrect dose administered, Injection site pain, Hypersensitivity, |
||||
TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, |
||||
| 414 | 25120249 |
US |
52 | 1 |
Rectal fissure, Injection site pain, Wrong technique in product usage process, |
||||
ADALIMUMAB, |
||||
| 415 | 25120274 |
58 | 2 | |
Injection site bruising, Injection site oedema, Injection site pain, |
||||
INCLISIRAN, |
||||
| 416 | 25120435 |
US |
61 | 2 |
Product dose omission issue, Injection site mass, Injection site pain, |
||||
DULAGLUTIDE, |
||||
| 417 | 25120441 |
US |
69 | 2 |
Product dose omission issue, Injection site pain, |
||||
TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, |
||||
| 418 | 25120557 |
US |
63 | 2 |
Injection site pain, |
||||
DULAGLUTIDE, |
||||
| 419 | 25120572 |
US |
44 | 2 |
Systemic lupus erythematosus, Injection site pain, Sleep disorder due to a general medical condition, Somnolence, Scar, Dry eye, Oral herpes, Product preparation error, |
||||
DUPILUMAB, |
||||
| 420 | 25120590 |
US |
60 | 2 |
Injection site pain, Incorrect dose administered, |
||||
DUPILUMAB, DUPILUMAB, MAGNESIUM, FISH OIL, IRON, LEVOTHYROXINE, MONTELUKAST SODIUM, CYANOCOBALAMIN, |
||||
| 421 | 25120681 |
US |
61 | 1 |
Accident, Sleep disorder due to general medical condition, insomnia type, Injection site reaction, Injection site pain, Nausea, Gastrooesophageal reflux disease, Eructation, Injection site haemorrhage, Abdominal pain upper, Abdominal distension, Injection site bruising, |
||||
TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, |
||||
| 422 | 25120819 |
US |
76 | 2 |
Injection site pain, Device difficult to use, Drug dose omission by device, Wrong technique in product usage process, |
||||
EVOLOCUMAB, |
||||
| 423 | 25120903 |
US |
40 | 2 |
Injection site pain, |
||||
GALCANEZUMAB-GNLM, GALCANEZUMAB-GNLM, |
||||
| 424 | 25120905 |
US |
51 | 2 |
Incorrect dose administered by device, Injection site erythema, Injection site pain, |
||||
GALCANEZUMAB-GNLM, GALCANEZUMAB-GNLM, GALCANEZUMAB-GNLM, GALCANEZUMAB-GNLM, GALCANEZUMAB-GNLM, GALCANEZUMAB-GNLM, |
||||
| 425 | 25120906 |
US |
61 | 2 |
Injection site pain, Injection site haemorrhage, Injection site erythema, |
||||
GALCANEZUMAB-GNLM, GALCANEZUMAB-GNLM, GALCANEZUMAB-GNLM, GALCANEZUMAB-GNLM, |
||||
| 426 | 25129570 |
37 | 2 | |
Injection site erythema, Injection site pruritus, Injection site swelling, Injection site pain, |
||||
TRALOKINUMAB-LDRM, |
||||
| 427 | 25109768 |
US |
42 | 2 |
Injection site pain, |
||||
DUPILUMAB, |
||||
| 428 | 25109811 |
US |
24 | 2 |
Underdose, Injection site haemorrhage, Injection site pain, |
||||
GALCANEZUMAB-GNLM, |
||||
| 429 | 25109886 |
US |
68 | 2 |
Injection site pain, Drug dose omission by device, Device difficult to use, |
||||
EVOLOCUMAB, EVOLOCUMAB, |
||||
| 430 | 25109930 |
US |
1 | |
Injection site pain, Product prescribing issue, |
||||
SOMATROPIN, SOMATROPIN, SOMATROPIN, SOMATROPIN, |
||||
| 431 | 25109963 |
US |
1 | |
Injection site pain, |
||||
RISPERIDONE, |
||||
| 432 | 25110162 |
US |
28 | 2 |
Injection site pain, |
||||
GALCANEZUMAB-GNLM, |
||||
| 433 | 25110236 |
US |
62 | 1 |
Injection site pain, |
||||
EVOLOCUMAB, EVOLOCUMAB, |
||||
| 434 | 25110263 |
US |
80 | 2 |
Device difficult to use, Injection site bruising, Dyslexia, Injection site pain, |
||||
EVOLOCUMAB, APIXABAN, |
||||
| 435 | 25110290 |
JP |
53 | 1 |
Hospitalisation, Parkinsonism, Thirst, Injection site pain, Refusal of treatment by patient, Sleep deficit, Off label use, |
||||
PALIPERIDONE PALMITATE, PALIPERIDONE PALMITATE, PALIPERIDONE PALMITATE, PALIPERIDONE PALMITATE, RISPERIDONE, RISPERIDONE, LEMBOREXANT, |
||||
| 436 | 25110293 |
US |
45 | |
Device difficult to use, Accidental exposure to product, Incorrect dose administered by device, Injection site pain, |
||||
ERENUMAB-AOOE, |
||||
| 437 | 25110294 |
US |
61 | 1 |
COVID-19, Injection site pain, Product communication issue, Accidental exposure to product, Drug dose omission by device, |
||||
EVOLOCUMAB, ADALIMUMAB, |
||||
| 438 | 25110312 |
US |
44 | 2 |
Injection site pain, |
||||
DULAGLUTIDE, |
||||
| 439 | 25110319 |
US |
28 | 2 |
Injection site pain, |
||||
TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, |
||||
| 440 | 25110385 |
GB |
61 | 2 |
Blindness, Burning sensation, Pain in extremity, Drug hypersensitivity, Injection site pain, Product availability issue, Incorrect dose administered, Off label use, |
||||
INSULIN DEGLUDEC, INSULIN DEGLUDEC, INSULIN DEGLUDEC, |
||||
| 441 | 25110479 |
US |
67 | 2 |
Injection site pain, |
||||
TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, |
||||
| 442 | 25110605 |
US |
2 | |
Injection site rash, Injection site pruritus, Injection site pain, Injection site bruising, Headache, Chills, |
||||
INTERFERON BETA-1A, INTERFERON BETA-1A, INTERFERON BETA-1A, INTERFERON BETA-1A, INTERFERON BETA-1A, INTERFERON BETA-1A, INTERFERON BETA-1A, INTERFERON BETA-1A, INTERFERON BETA-1A, INTERFERON BETA-1A, INTERFERON BETA-1A, INTERFERON BETA-1A, INTERFERON BETA-1A, INTERFERON BETA-1A, |
||||
| 443 | 25110705 |
US |
55 | 2 |
Product dose omission issue, Injection site pruritus, Injection site pain, |
||||
TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, METFORMIN, METFORMIN ER 500 MG, METFORMIN ER 750 MG, |
||||
| 444 | 25110707 |
US |
49 | 1 |
Injection site pain, |
||||
TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, |
||||
| 445 | 25110718 |
US |
48 | 1 |
Injection site pain, |
||||
TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, |
||||
| 446 | 25110723 |
US |
||
Dyspnoea, Injection site pain, Drug dose omission by device, Device delivery system issue, Wrong technique in device usage process, |
||||
TEZEPELUMAB-EKKO, TEZEPELUMAB-EKKO, |
||||
| 447 | 25110864 |
US |
68 | 1 |
Injection site pain, Injection site haemorrhage, |
||||
IXEKIZUMAB, IXEKIZUMAB, IXEKIZUMAB, IXEKIZUMAB, |
||||
| 448 | 25110949 |
US |
80 | 2 |
Injection site pain, |
||||
DULAGLUTIDE, |
||||
| 449 | 25110994 |
GR |
6 | 2 |
Injection site pain, Incorrect dose administered, |
||||
SOMATROPIN, SOMATROPIN, |
||||
| 450 | 25111042 |
US |
||
Injection site pain, |
||||
LEBRIKIZUMAB-LBKZ, |
||||
| 451 | 25111197 |
US |
52 | 2 |
Visual impairment, Injection site pain, Drug dose omission by device, Device difficult to use, Accidental exposure to product, |
||||
ERENUMAB-AOOE, |
||||
| 452 | 25111253 |
US |
63 | 2 |
Extra dose administered, Injection site pain, Cataract, |
||||
DULAGLUTIDE, DULAGLUTIDE, |
||||
| 453 | 25111376 |
US |
47 | |
Injection site bruising, Injection site pain, |
||||
TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, |
||||
| 454 | 25111421 |
CA |
65 | 1 |
Injection site pain, |
||||
LEUPROLIDE ACETATE, |
||||
| 455 | 25111423 |
CA |
64 | 1 |
Injection site pain, |
||||
LEUPROLIDE ACETATE, LEUPROLIDE ACETATE, |
||||
| 456 | 25111427 |
CA |
83 | 1 |
Injection site pain, Injection site pain, |
||||
LEUPROLIDE ACETATE, LEUPROLIDE ACETATE, |
||||
| 457 | 25111428 |
CA |
74 | 1 |
Injection site pain, |
||||
LEUPROLIDE ACETATE, |
||||
| 458 | 25111429 |
CA |
86 | 1 |
Injection site pain, |
||||
LEUPROLIDE ACETATE, LEUPROLIDE ACETATE, |
||||
| 459 | 25111430 |
CA |
80 | 1 |
Injection site pain, |
||||
LEUPROLIDE ACETATE, LEUPROLIDE ACETATE, |
||||
| 460 | 25111434 |
CA |
80 | 1 |
Injection site discomfort, Injection site pain, |
||||
LEUPROLIDE ACETATE, |
||||
| 461 | 25111441 |
NI |
2 | |
Injection site pain, |
||||
LEUPROLIDE ACETATE, LEUPROLIDE ACETATE, |
||||
| 462 | 25111691 |
US |
2 | |
Autoimmune colitis, Injection site pain, Injection site rash, Injection site swelling, Thyroid function test abnormal, Back pain, Fatigue, |
||||
CABOZANTINIB, NIVOLUMAB, IPILIMUMAB, |
||||
| 463 | 25111746 |
US |
42 | 2 |
Injection site pain, |
||||
GALCANEZUMAB-GNLM, GALCANEZUMAB-GNLM, |
||||
| 464 | 25111748 |
US |
49 | 2 |
Injection site pain, |
||||
TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, |
||||
| 465 | 25111920 |
US |
60 | 2 |
Device difficult to use, Drug dose omission by device, Injection site pain, |
||||
EVOLOCUMAB, EVOLOCUMAB, EVOLOCUMAB, |
||||
| 466 | 25112020 |
CA |
1 | |
Rheumatoid arthritis, Injection site pain, |
||||
| 467 | 25112097 |
US |
64 | 2 |
Incorrect dose administered, Injection site erythema, Injection site pain, |
||||
TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, |
||||
| 468 | 25112198 |
US |
58 | 1 |
Wrong technique in product usage process, Arthralgia, Device issue, Injection site pain, |
||||
ADALIMUMAB, |
||||
| 469 | 25112280 |
US |
12 | 2 |
Injection site pain, |
||||
SOMATROGON-GHLA, |
||||
| 470 | 25112465 |
US |
33 | 2 |
Injection site pain, Injection site haemorrhage, Injection site rash, Psoriasis, |
||||
BIMEKIZUMAB, |
||||
| 471 | 25112541 |
US |
2 | |
Injection site pain, Fatigue, Weight decreased, Erythema, Pruritus, Burning sensation, Skin lesion, Psoriasis, |
||||
BIMEKIZUMAB, BIMEKIZUMAB, BIMEKIZUMAB, |
||||
| 472 | 25112594 |
US |
72 | 2 |
Injection site pain, Incorrect dose administered, |
||||
BIMEKIZUMAB, |
||||
| 473 | 25112635 |
US |
2 | |
Injection site pain, Lethargy, Product dispensing error, |
||||
BIMEKIZUMAB, |
||||
| 474 | 25112646 |
US |
46 | 2 |
Vomiting, Gastrooesophageal reflux disease, Hernia, Muscle spasms, Injection site pain, |
||||
BIMEKIZUMAB, |
||||
| 475 | 25112658 |
CA |
29 | 2 |
Urticaria, Weight decreased, Injection site pain, Incorrect dose administered, Needle issue, Erythema, Skin irritation, Pruritus, |
||||
OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, CETIRIZINE HYDROCHLORIDE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE TABLETS, CETIRIZINE HYDROCHLORIDE ALLERGY, DIPHENHYDRAMINE HYDROCHLORIDE, PREDNISONE, LORATADINE, LORATADINE TABLET, CIPROFLOXACIN HYDROCHLORIDE, |
||||
| 476 | 25112683 |
US |
42 | 2 |
Injection site pain, Inappropriate schedule of product administration, Device issue, |
||||
BIMEKIZUMAB, |
||||
| 477 | 25112763 |
US |
2 | |
Injection site pain, Acne, Headache, Arthralgia, |
||||
BIMEKIZUMAB, |
||||
| 478 | 25112768 |
US |
2 | |
Injection site bruising, Injection site pain, Device issue, Incorrect dose administered, Product dose omission issue, |
||||
BIMEKIZUMAB, BIMEKIZUMAB, BIMEKIZUMAB, BIMEKIZUMAB, |
||||
| 479 | 25112913 |
US |
2 | |
Injection site pain, Nausea, Product dose omission issue, Product availability issue, |
||||
BIMEKIZUMAB, |
||||
| 480 | 25112946 |
US |
1 | |
Injection site pain, Incorrect dose administered, Wrong technique in product usage process, |
||||
BIMEKIZUMAB, METFORMIN HYDROCHLORIDE, METFORMIN, METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS, METFORMIN HYDROCHLORIDE TABLET, METFORMIN HYDROCHLORIDE TABLETS, FLUOXETINE HYDROCHLORIDE, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, NABUMETONE, DICYCLOMINE HYDROCHLORIDE, WARFARIN SODIUM, WARFARIN, GABAPENTIN, METHOTREXATE, METHOTREXATE SODIUM, FUROSEMIDE, TAMSULOSIN HYDROCHLORIDE, TIRZEPATIDE, GLIPIZIDE, CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE, METOPROLOL SUCCINATE, METOPROLOL SUCCINATE ER TABLETS, ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM, FILM COATED, PREDNISONE, IRON, ERGOCALCIFEROL, LISINOPRIL, |
||||
| 481 | 25113197 |
US |
23 | 1 |
Injection site pain, Incorrect dose administered, Drug ineffective, |
||||
BIMEKIZUMAB, ATOMOXETINE HYDROCHLORIDE, METOPROLOL TARTRATE, METOROPROLOL TARTRATE, METOPROLOL, |
||||
| 482 | 25113214 |
US |
2 | |
Injection site pain, Discomfort, Wrong technique in product usage process, |
||||
BIMEKIZUMAB, |
||||
| 483 | 25113216 |
US |
38 | 1 |
Injection site pain, Pruritus, |
||||
BIMEKIZUMAB, |
||||
| 484 | 25113233 |
US |
2 | |
Erythema, Swelling, Injection site pruritus, Injection site pain, Injection site reaction, |
||||
BIMEKIZUMAB, |
||||
| 485 | 25113291 |
US |
2 | |
Injection site pain, Product dose omission issue, |
||||
BIMEKIZUMAB, |
||||
| 486 | 25113298 |
US |
1 | |
Injection site pain, Product dose omission issue, |
||||
BIMEKIZUMAB, |
||||
| 487 | 25113398 |
FR |
61 | 2 |
Infusion related reaction, Inappropriate schedule of product administration, Influenza, Abdominal discomfort, Injection site pain, Swelling, Drug ineffective, Wrong technique in product usage process, |
||||
| 488 | 25113505 |
US |
39 | |
Injection site pain, Nervousness, Wrong technique in device usage process, Incorrect dose administered by device, Device leakage, |
||||
EXENATIDE, |
||||
| 489 | 25113692 |
US |
2 | |
Blood glucose increased, Blood glucose decreased, Injection site pain, |
||||
INSULIN LISPRO, INSULIN LISPRO, METFORMIN, METFORMIN ER 500 MG, METFORMIN ER 750 MG, |
||||
| 490 | 25113701 |
US |
47 | |
Incorrect dose administered, Injection site pain, Injection site haemorrhage, |
||||
TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, |
||||
| 491 | 25113862 |
US |
57 | 2 |
Injection site pain, |
||||
TIRZEPATIDE, |
||||
| 492 | 25114115 |
US |
73 | 2 |
Injection site pain, |
||||
INSULIN LISPRO, INSULIN DETEMIR, |
||||
| 493 | 25114121 |
US |
66 | |
Sensitive skin, Injection site pain, |
||||
TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, |
||||
| 494 | 25114146 |
CA |
80 | 2 |
Drug ineffective, Abscess limb, Feeling hot, Localised infection, Malaise, Product dose omission issue, Fear of injection, Fine motor skill dysfunction, Injection site pain, Injection site reaction, Musculoskeletal stiffness, Nodule, Peripheral swelling, Limb injury, Injury associated with device, Inappropriate schedule of product administration, |
||||
METHOTREXATE SODIUM, |
||||
| 495 | 25114173 |
CN |
80 | 2 |
Injection site discolouration, Injection site pain, |
||||
ENOXAPARIN SODIUM, |
||||
| 496 | 25114196 |
US |
35 | 2 |
Seizure, Pancreatitis, Injection site pain, Injection site swelling, Injection site pruritus, Malnutrition, |
||||
BIMEKIZUMAB, |
||||
| 497 | 25114205 |
US |
2 | |
Injection site pain, |
||||
DUPILUMAB, |
||||
| 498 | 25114208 |
US |
11 | 1 |
Injection site pain, |
||||
DUPILUMAB, |
||||
| 499 | 25114216 |
US |
38 | 2 |
Lacrimation increased, Injection site pain, Eczema, Erythema, Pruritus, Dermatitis, Skin fissures, Skin ulcer, Eye irritation, Eye pruritus, |
||||
DUPILUMAB, DUPILUMAB, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, |
||||
| 500 | 25114232 |
US |
67 | 2 |
Injection site pain, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2025-04-28